Olmesartan Medoxomilo Teva

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It treats hypertension in adult patients and helps lower the risk of cardiovascular events.

GNH USA supplies Olmesartan Medoxomil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an ARB used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure to target levels. - Essential hypertension: improves long‑term cardiovascular outcomes. - High blood pressure: assists patients in achieving recommended blood‑pressure goals.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness without exertion. - Abdominal pain: mild discomfort in the stomach area. - Nasal congestion: stuffy nose or sinus pressure. - Back pain: occasional soreness in the lumbar region.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Hyperkalemia: elevated potassium levels that may cause cardiac arrhythmia. - Acute renal impairment: sudden decline in kidney function. - Severe hypotension: markedly low blood pressure leading to fainting. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or urticaria.

Before initiating therapy with Olmesartan medoxomil, consider the following safety measures.

- Blood pressure monitoring: check regularly to ensure therapeutic response. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with kidney disease. - Electrolyte surveillance: monitor potassium levels to avoid hyperkalemia. - Hepatic impairment caution: use with care in patients with severe liver dysfunction. - Pregnancy and lactation warning: avoid use during pregnancy; discuss risks with a healthcare professional if breastfeeding. - Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Olmesartan medoxomil can interact with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent use can lead to additive risk of angioedema and hyperkalemia. - Lithium: increased lithium levels and potential toxicity. - NSAIDs (high‑dose or chronic): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance blood‑pressure lowering effect, requiring dose adjustment. - CYP450 inhibitors (e.g., azole antifungals): may modestly increase olmesartan exposure. - Antihypertensive agents (beta‑blockers, calcium‑channel blockers): additive hypotensive effect, monitor for symptomatic hypotension.